Αρχική World News FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a... World News FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation Από Ogkologos - 20 Νοεμβρίου, 2025 489 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR How the National Cancer Act Has Made a Difference in Cancer... 18 Φεβρουαρίου, 2021 Making the most of your ‘eureka’ moment: getting from the science... 22 Σεπτεμβρίου, 2021 Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in... 22 Αυγούστου, 2024 For Women With Dense Breasts, An MRI May Be A Better... 29 Νοεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism What’s at the Root of Ovarian Cancer? New Study May Have... Kelly Preston, Actress And Wife Of John Travolta, Dies From Breast... Cancer Research UK honours Her Majesty The Queen, the charity’s Patron